Oct 27, 2021 / 12:30PM GMT
Jordan Zwick - InflaRx N.V. - Chief Strategy Officer
Hello. Thank you for joining us to discuss the top-line results from the third cohort of the Phase IIa open-label study evaluating vilobelimab in patients with pyoderma gangrenosum. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website following the call.
Before we begin, I'd like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional details.
With me on the call presenting the data is Professor Niels Riedemann, our CEO and Founder; along with Dr. Hoda Tawfik, our Senior Program Director of Dermatology; our Chief Clinical Development Officer, Dr. Korinna Pilz; and our CFO, Dr. Thomas Taapken, will join the Q&A section at the end of the call. Now I'll turn the call over to Niels.
Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call Transcript
Oct 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers